LONG MINI-FUTURE - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 09:24:06 14/06/2024 BST | ||
| 11.03 EUR | -0.81% |
|
| Current month | +30.67% | ||
| 1 month | +71.60% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 11.03 | -0.81% |
| 13/06/24 | 11.12 | +2.11% |
| 12/06/24 | 10.89 | -3.97% |
| 11/06/24 | 11.34 | -0.96% |
| 10/06/24 | 11.45 | -1.21% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 09:24 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM656J |
| ISIN | DE000VM656J0 |
| Date issued | 15/12/2023 |
| Strike | 361.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.71 € |
|---|---|
| Lowest since issue | 3.19 € |
| Spread | 0.18 € |
| Spread % | 1.65% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
479
USD
Average target price
463.4
USD
Spread / Average Target
-3.26%
- Stock Market
- Certificates
- Certificat
